Literature DB >> 22867711

The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system.

Hwan-Ching Tai1, Alberto Serrano-Pozo, Tadafumi Hashimoto, Matthew P Frosch, Tara L Spires-Jones, Bradley T Hyman.   

Abstract

In Alzheimer disease (AD), deposition of neurofibrillary tangles and loss of synapses in the neocortex and limbic system each correlate strongly with cognitive impairment. Tangles are composed of misfolded hyperphosphorylated tau proteins; however, the link between tau abnormalities and synaptic dysfunction remains unclear. We examined the location of tau in control and AD cortices using biochemical and morphologic methods. We found that, in addition to its well-described axonal localization, normal tau is present at both presynaptic and postsynaptic terminals in control human brains. In AD, tau becomes hyperphosphorylated and misfolded at both presynaptic and postsynaptic terminals, and this abnormally posttranslationally modified tau is enriched in synaptoneurosomal fractions. Synaptic tau seems to be hyperphosphorylated and ubiquitinated, and forms stable oligomers resistant to SDS denaturation. The accumulation of hyperphosphorylated tau oligomers at human AD synapses is associated with increased ubiquitinated substrates and increased proteasome components, consistent with dysfunction of the ubiquitin-proteasome system. Our findings suggest that synaptic hyperphosphorylated tau oligomers may be an important mediator of the proteotoxicity that disrupts synapses in AD.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22867711      PMCID: PMC3463637          DOI: 10.1016/j.ajpath.2012.06.033

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  47 in total

Review 1.  Neuropathology of Alzheimer's disease: what is new since A. Alzheimer?

Authors:  E Braak; K Griffing; K Arai; J Bohl; H Bratzke; H Braak
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1999       Impact factor: 5.270

2.  Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease.

Authors:  P Giannakopoulos; F R Herrmann; T Bussière; C Bouras; E Kövari; D P Perl; J H Morrison; G Gold; P R Hof
Journal:  Neurology       Date:  2003-05-13       Impact factor: 9.910

3.  Presynaptic microtubules: organisation and assembly/disassembly.

Authors:  P R Gordon-Weeks; R D Burgoyne; E G Gray
Journal:  Neuroscience       Date:  1982-03       Impact factor: 3.590

4.  Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes.

Authors:  K Duff; H Knight; L M Refolo; S Sanders; X Yu; M Picciano; B Malester; M Hutton; J Adamson; M Goedert; K Burki; P Davies
Journal:  Neurobiol Dis       Date:  2000-04       Impact factor: 5.996

5.  Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease.

Authors:  Susi Keck; Robert Nitsch; Tilman Grune; Oliver Ullrich
Journal:  J Neurochem       Date:  2003-04       Impact factor: 5.372

6.  Differential subcellular localization of tubulin and the microtubule-associated protein MAP2 in brain tissue as revealed by immunocytochemistry with monoclonal hybridoma antibodies.

Authors:  A Caceres; L I Binder; M R Payne; P Bender; L Rebhun; O Steward
Journal:  J Neurosci       Date:  1984-02       Impact factor: 6.167

7.  Serotonin uptake and release by biochemically characterized nerve endings isolated from rat brain by concomitant flotation and sedimentation centrifugation.

Authors:  D Lathia; W Wesemann
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

8.  Biochemical characterization of a filtered synaptoneurosome preparation from guinea pig cerebral cortex: cyclic adenosine 3':5'-monophosphate-generating systems, receptors, and enzymes.

Authors:  E B Hollingsworth; E T McNeal; J L Burton; R J Williams; J W Daly; C R Creveling
Journal:  J Neurosci       Date:  1985-08       Impact factor: 6.167

Review 9.  Role of tau protein in both physiological and pathological conditions.

Authors:  Jesus Avila; Jose J Lucas; Mar Perez; Felix Hernandez
Journal:  Physiol Rev       Date:  2004-04       Impact factor: 37.312

10.  Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain.

Authors:  M Ingelsson; H Fukumoto; K L Newell; J H Growdon; E T Hedley-Whyte; M P Frosch; M S Albert; B T Hyman; M C Irizarry
Journal:  Neurology       Date:  2004-03-23       Impact factor: 9.910

View more
  154 in total

1.  Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease.

Authors:  Sophie Sokolow; Kristen M Henkins; Tina Bilousova; Bianca Gonzalez; Harry V Vinters; Carol A Miller; Lindsey Cornwell; Wayne W Poon; Karen H Gylys
Journal:  J Neurochem       Date:  2015-01-13       Impact factor: 5.372

2.  Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.

Authors:  Natura Myeku; Catherine L Clelland; Sheina Emrani; Nikolay V Kukushkin; Wai Haung Yu; Alfred L Goldberg; Karen E Duff
Journal:  Nat Med       Date:  2015-12-21       Impact factor: 53.440

Review 3.  Comparative Microarray Analysis Identifies Commonalities in Neuronal Injury: Evidence for Oxidative Stress, Dysfunction of Calcium Signalling, and Inhibition of Autophagy-Lysosomal Pathway.

Authors:  Yann Wan Yap; Roxana M Llanos; Sharon La Fontaine; Michael A Cater; Philip M Beart; Nam Sang Cheung
Journal:  Neurochem Res       Date:  2015-08-29       Impact factor: 3.996

Review 4.  The intersection of amyloid beta and tau at synapses in Alzheimer's disease.

Authors:  Tara L Spires-Jones; Bradley T Hyman
Journal:  Neuron       Date:  2014-05-21       Impact factor: 17.173

Review 5.  Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.

Authors:  Shu-Hui Xin; Lin Tan; Xipeng Cao; Jin-Tai Yu; Lan Tan
Journal:  Neurotox Res       Date:  2018-04-07       Impact factor: 3.911

Review 6.  Ubiquitination in disease pathogenesis and treatment.

Authors:  Doris Popovic; Domagoj Vucic; Ivan Dikic
Journal:  Nat Med       Date:  2014-11-06       Impact factor: 53.440

Review 7.  Inhibition of protein misfolding and aggregation by natural phenolic compounds.

Authors:  Zohra Dhouafli; Karina Cuanalo-Contreras; El Akrem Hayouni; Charles E Mays; Claudio Soto; Ines Moreno-Gonzalez
Journal:  Cell Mol Life Sci       Date:  2018-07-20       Impact factor: 9.261

Review 8.  It's all about tau.

Authors:  Cheril Tapia-Rojas; Fabian Cabezas-Opazo; Carol A Deaton; Erick H Vergara; Gail V W Johnson; Rodrigo A Quintanilla
Journal:  Prog Neurobiol       Date:  2018-12-31       Impact factor: 11.685

9.  Changes in proteome solubility indicate widespread proteostatic disruption in mouse models of neurodegenerative disease.

Authors:  Michael C Pace; Guilian Xu; Susan Fromholt; John Howard; Keith Crosby; Benoit I Giasson; Jada Lewis; David R Borchelt
Journal:  Acta Neuropathol       Date:  2018-08-23       Impact factor: 17.088

Review 10.  The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease.

Authors:  Johanna L Crimins; Amy Pooler; Manuela Polydoro; Jennifer I Luebke; Tara L Spires-Jones
Journal:  Ageing Res Rev       Date:  2013-03-22       Impact factor: 10.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.